Posters

New treatment of corneal ectasia after LASIK by induction of new corneal fibrogenesis

Poster Details

First Author: E.Jarade LEBANON

Co Author(s):                        

Abstract Details

Purpose:

After LASIK, the flap is considered as biomechanically dead tissue and its creation largely contribute to the development of actasia. Herewith we describe a new technique of: 1) corneal collagen fibrogenisis, 2) inter-fibrillar collagen bounds restoring and 3) biomechanically reintegrating corneal flap tissue to treat corneal actasia

Setting:

Beirut Eye&ENT Specialist Hospital

Methods:

Progressive corneal ectasia after LASIK were treated between January 2016 and March 2017 by 360 degrees vertically puncturing the paracentral corneal zone (4 to 9 mm) at a depth of 350 to 420 microns using a bended 25-gauge needle or diamond blade. 3 to 4 different paracentral circumferential rows were performed with varying depth depends on the location of the cone and the regional depth of the cornea. More puncturing was performed at the level of the corneal steep area. Complete ophthalmic evaluations were performed before treatment and at each follow up visit up to 1 year

Results:

5 eyes of 3 patients with progressive corneal ectasia after LASIK were included in this study. The average values of UCVA, CDVA, spherical equivalent refraction, Kmin, Ksteep and Kmax were as follow: 0.16; 0.49; -0.13; 39.5; 43.4; 51.4 respectively preoperatively and 0.3; 0.82; 2.37; 37.84; 43.06 and 52.98 at last FU visit. Very significant improvement in UCVA, CDVA and resultant hyperopic shift were observed in all treated eyes with significant corneal flattening. New corneal collagen fibrogenetic load was documented by corneal OCT and confocal microscopy

Conclusions:

Our new technique of corneal fibrogenesis is proven to be effective and safe in restoring corneal biomechanical properties and is considered as a new merging technique for the treatment of corneal ecatasia. Animal studies, more clinical data with longer follow up are needed to validate and standardize this new treatment of corneal ectasia

Financial Disclosure:

None